Catalent, Inc. (NYSE:CTLT) Receives $63.40 Average Target Price from Brokerages

Catalent, Inc. (NYSE:CTLT) has been assigned an average rating of “Hold” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $63.40.

Several research analysts have recently issued reports on CTLT shares. StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a research note on Monday. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd.

Catalent Trading Up 0.2 %

Shares of CTLT stock opened at $61.80 on Monday. The company has a 50-day moving average of $60.00 and a two-hundred day moving average of $58.62. Catalent has a 1-year low of $36.74 and a 1-year high of $62.08. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The firm has a market cap of $11.22 billion, a PE ratio of -27.35, a price-to-earnings-growth ratio of 2.44 and a beta of 1.15.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.10) earnings per share. On average, analysts predict that Catalent will post 0.84 EPS for the current year.

Insider Transactions at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,114 shares of company stock valued at $305,931. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC grew its holdings in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after purchasing an additional 2,299,784 shares during the period. Bank of Montreal Can grew its position in Catalent by 181.5% during the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock valued at $109,388,000 after buying an additional 1,169,044 shares during the period. National Bank of Canada FI raised its stake in shares of Catalent by 300.0% in the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after buying an additional 1,095,578 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Catalent by 166.5% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after acquiring an additional 863,624 shares during the period. Finally, ING Groep NV lifted its stake in Catalent by 162.5% in the 3rd quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock worth $68,475,000 after purchasing an additional 699,851 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.